» Articles » PMID: 2538247

Multistage Carcinogenesis Induced by Ras and Myc Oncogenes in a Reconstituted Organ

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 1989 Mar 24
PMID 2538247
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

ras and myc oncogenes were able to induce distinct phenotypic alterations, resembling different types of premalignant lesions, when introduced into approximately 0.1% of the cells used to reconstitute the mouse prostate gland. While ras induced dysplasia in combination with angiogenesis, myc induced a hyperplasia of the otherwise normally developed organ. ras and myc together induced primarily carcinomas. However, tumor progression was also associated with additional genetic alterations involving gene amplification. Our data indicate that specific types of benign premalignant lesions may reflect the activation of different single oncogenes, and that the consecutive activation of multiple oncogenes could be a causal event in the step-like progression of tumorigenesis.

Citing Articles

Hyaluronidase inhibitor delphinidin inhibits cancer metastasis.

McGuire J, Taguchi T, Tombline G, Paige V, Janelsins M, Gilmore N Sci Rep. 2024; 14(1):14958.

PMID: 38942920 PMC: 11213947. DOI: 10.1038/s41598-024-64924-6.


Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers.

Praharaj M, Shen F, Lee A, Zhao L, Nirschl T, Theodros D Cancer Immunol Res. 2024; 12(7):854-875.

PMID: 38701369 PMC: 11217738. DOI: 10.1158/2326-6066.CIR-23-1105.


Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis.

Izadmehr S, Fernandez-Hernandez H, Wiredja D, Kirschenbaum A, Lee-Poturalski C, Tavassoli P bioRxiv. 2024; .

PMID: 38352401 PMC: 10862900. DOI: 10.1101/2024.01.30.577982.


Microfluidic-based human prostate-cancer-on-chip.

Jiang L, Khawaja H, Tahsin S, Clarkson T, Miranti C, Zohar Y Front Bioeng Biotechnol. 2024; 12:1302223.

PMID: 38322789 PMC: 10844564. DOI: 10.3389/fbioe.2024.1302223.


Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer.

Zhu Y, Zhao Y, Wen J, Liu S, Huang T, Hatial I Sci Immunol. 2023; 8(81):eade4656.

PMID: 36897957 PMC: 10336890. DOI: 10.1126/sciimmunol.ade4656.